Lurbinectedin
FDA-approved product (powder, intravenous), marketed as Zepzelca.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 4 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Cancer
- Neoplasm
- Small cell lung carcinoma
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Other antineoplastic agents
- FDA pharmacologic class
- Alkylating Drug FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against K. pneumoniae, MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA56.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli55.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae47.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- M. tuberculosis66.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Lurbinectedin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- VenetoclaxExisting use: Cancer, Chronic lymphocytic leukemia, Neoplasm45.9% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Desmopressin AcetateExisting use: Central diabetes insipidus, Diabetes insipidus, Enuresis and 5 more45.6% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Dihydrocodeine BitartrateExisting use: Pain45.5% AI-predicted activityagainst K. pneumoniae3 registered studies
- CabotegravirExisting use: HIV infection, HIV-1 infection, Viral disease45.5% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Paliperidone PalmitateExisting use: Mental or behavioural disorder, Psychosis, Schizoaffective disorder and 1 more45.2% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Aripiprazole LauroxilExisting use: Aggressive behavior, Agitation, Autism and 8 more45.0% AI-predicted activityagainst K. pneumoniae10 registered studies
- EverolimusExisting use: Adenoma sebaceum, Anaplastic astrocytoma, Angiomyolipoma and 18 more44.7% AI-predicted activityagainst K. pneumoniae50+ registered studies
- AdagrasibExisting use: Neoplasm, Non-small cell lung carcinoma44.7% AI-predicted activityagainst K. pneumoniae40 registered studies
- Ibrexafungerp CitrateExisting use: Vulvovaginal candidiasis44.7% AI-predicted activityagainst K. pneumoniaeNo documented evidence found
- OxycodoneExisting use: Chronic pain, Drug dependence, Pain and 1 more44.6% AI-predicted activityagainst K. pneumoniae50+ registered studies
- IloperidoneExisting use: Psychosis, Schizophrenia44.6% AI-predicted activityagainst K. pneumoniae32 registered studies
- Trametinib Dimethyl SulfoxideExisting use: Cancer, Cutaneous melanoma, Glioblastoma multiforme and 5 more44.6% AI-predicted activityagainst K. pneumoniae16 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer
NCT01525589 · start 2012-06-13
Registered record
- Registry ID
- NCT01525589
- Conditions
- Breast Cancer
- Interventions
- PM01183
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2012-06-13
- Completion
- 2018-10
- Enrolment
- 111
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBreast CancerInterventionPM01183PhasePhase 2Registry statusCompletedStudy of PM01183 in Non-Colorectal Cancer Patients as a Days 1 and 8 Intravenous Short Infusion Every 3 Weeks
NCT01405391 · start 2011-11
Registered record
- Registry ID
- NCT01405391
- Conditions
- Major Advanced Solid Tumors Other Than Colorectal
- Interventions
- PM01183
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2011-11
- Completion
- 2016-01
- Enrolment
- 42
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMajor Advanced Solid Tumors Other Than ColorectalInterventionPM01183PhasePhase 1Registry statusCompletedStudy Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors
NCT01970540 · start 2011-05-25
Registered record
- Registry ID
- NCT01970540
- Conditions
- Endometrial Adenocarcinomas; Neuroendocrine Tumors; Small-cell Lung Cancer With Less Than 2 Prior Cytotoxic-containing Lines of Therapy
- Interventions
- lurbinectedin (PM01183); Doxorubicin
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2011-05-25
- Completion
- 2017-08-09
- Enrolment
- 122
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionEndometrial Adenocarcinomas; Neuroendocrine Tumors; Small-cell Lung Cancer With Less Than 2 Prior Cytotoxic-containing Lines of TherapyInterventionlurbinectedin (PM01183); DoxorubicinPhasePhase 1Registry statusCompletedClinical Study of PM01183 in Patients With Acute Leukemia or Relapsed/Refractory Myelodysplastic Syndrome
NCT01314599 · start 2011-05
Registered record
- Registry ID
- NCT01314599
- Conditions
- Acute Leukemia
- Interventions
- PM01183 1 mg Powder for concentrate for solution for infusion and PM01183 4 mg Powder for concentrate for solution for infusion
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2011-05
- Completion
- 2015-07
- Enrolment
- 45
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAcute LeukemiaInterventionPM01183 1 mg Powder for concentrate for solution for infusion and PM01183 4 mg Powder for concentrate for solution for infusionPhasePhase 1Registry statusCompletedEscalating Doses of PM01183 in Combination With Gemcitabine in Patients With Specific Unresectable Solid Tumors
NCT01970553 · start 2011-05
Registered record
- Registry ID
- NCT01970553
- Conditions
- Specific Advanced Solid Tumors
- Interventions
- lurbinectedin (PM01183); Gemcitabine
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2011-05
- Completion
- 2013-10
- Enrolment
- 47
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSpecific Advanced Solid TumorsInterventionlurbinectedin (PM01183); GemcitabinePhasePhase 1Registry statusCompleted